Drugs for Immunotherapy Global Market Report 2025

Description

Immunotherapy drugs constitute a category of medications designed to modulate the immune system, either by enhancing or suppressing it, to bolster the body's defense against cancer, infections, and various ailments. This approach to cancer treatment harnesses the body's immune response to combat the disease.

The primary classes of immunotherapy drugs encompass monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and other specialized treatments. Monoclonal antibodies, for instance, are produced by replicating a single white blood cell, allowing the lineage of each antibody to be traced back to its originating parent cell. These drugs find application across diverse medical domains such as cancer treatment, autoimmune conditions, inflammatory diseases, and combating infections. They are employed across various healthcare settings including hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The drugs for immunotherapy market size has grown rapidly in recent years. It will grow from $255.14 billion in 2024 to $281.43 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the rising incidence of cancer, unmet medical needs, cancer immunotherapy awareness, higher adoption rates of immunotherapeutic approaches, and rising investment by pharmaceutical giants.

The drugs for immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $445.12 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to combination therapies, personalized medicine, global expansion, biomarker-driven therapies, and increasing clinical trials. Major trends in the forecast period include advancements in immunology, advancements in car-t cell therapies, targeted immunotherapies, immunotherapy combinations, and neoantigen vaccines.

The burgeoning prevalence of cancer worldwide stands as the primary impetus behind the escalating demand for drugs in the immunotherapy market. The proliferation of cancer cases, attributed to factors like obesity, smoking, alcohol consumption, and dietary habits, is projected to soar significantly. Reports from Macmillan Cancer Support in October 2022 estimated a steep rise in cancer cases, predicting 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. With breast, lung, colon, rectum, and prostate cancers ranking as the most widespread types, lifestyle elements such as tobacco use, high BMI, limited fruit and vegetable intake, alcohol consumption, and lack of exercise contribute to roughly one-third of cancer-related deaths. This escalation in cancer incidence is set to drive up the demand for immunotherapy drugs, consequently fueling market growth.

The rising healthcare expenditure is expected to drive the growth of the immunotherapy drugs market in the future. Healthcare expenditure encompasses the total amount spent on healthcare goods and services within a specific region or country over a defined period. This includes expenses for doctor visits, hospital stays, surgeries, diagnostic tests, and treatments. Financial resources allocated for healthcare come from individuals, healthcare providers, insurance companies, and government agencies to cover costs related to immunotherapy drugs and treatments. For instance, a report from the Centers for Medicare & Medicaid Services in December 2022 indicated that U.S. healthcare spending increased by 4.1% to reach $4.5 trillion in 2022, surpassing the 3.2% growth seen in 2021. As a result, the rise in healthcare expenditure is driving the growth of the drugs for immunotherapy market.

Prominent entities within the immunotherapy drugs market are strategically focused on innovating novel products such as Keytruda (pembrolizumab), aimed at delivering dependable services to consumers. Keytruda, an immune checkpoint inhibitor categorized under immunotherapy, was launched by Merck & Co., Inc. in January 2023. Approved by the US Food and Drug Administration, this breakthrough therapy assists the immune system in combating cancer cells, notably approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This development stands as a substantial leap in cancer treatment, poised to positively impact the healthcare industry's landscape.

Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilize Illumina's next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer's portfolio of assets related to allogeneic CAR-T therapy.

In December 2024, Pfizer Inc., a pharmaceutical company based in the United States, completed the acquisition of Seagen for $43 billion. This acquisition is intended to enhance Pfizer's oncology portfolio by incorporating advanced immunotherapy treatments that utilize Seagen's innovative antibody-drug conjugates (ADCs) for targeted cancer therapy. Seagen Inc. is a biotechnology firm located in the U.S. that focuses on the production of antibody-drug conjugates (ADCs).

Major companies operating in the drugs for immunotherapy market include F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, Johnson & Johnson, UbiVac, Pfizer Inc., Sanofi SA, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Gilead Sciences Inc., Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

North America was the largest region in the immunotherapy market in 2024. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drugs for Immunotherapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drugs for immunotherapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drugs for immunotherapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drugs for immunotherapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Monoclonal Antibodies; Interferons; Interleukins; Vaccines; Checkpoint Inhibitors; Other Types
2) By Therapy Area: Cancer; Autoimmune & Inflammatory Diseases; Infectious Diseases; Other Therapy Areas
3) By End User: Hospitals & Clinics; Ambulatory Surgical Centers; Other End Users
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies; Conjugated Monoclonal Antibodies; Bispecific Monoclonal Antibodies
2) By Interferons: Interferon Alfa; Interferon Beta; Interferon Gamma
3) By Interleukins: Interleukin-2 (IL-2); Interleukin-6 (IL-6); Interleukin-12 (IL-12)
4) By Vaccines: Preventive Vaccines; Therapeutic Vaccines
5) By Checkpoint Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
6) By Other Types: Cancer Cell Therapies; Cytokine Therapy; T-Cell Receptor Therapy
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; Amgen Inc.; AbbVie Inc.; Merck & Co. Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r32910

1. Executive Summary

2. Drugs for Immunotherapy Market Characteristics

3. Drugs for Immunotherapy Market Trends And Strategies

4. Drugs for Immunotherapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Drugs for Immunotherapy Growth Analysis And Strategic Analysis Framework

5.1. Global Drugs for Immunotherapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Drugs for Immunotherapy Market Growth Rate Analysis
5.4. Global Drugs for Immunotherapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Drugs for Immunotherapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Drugs for Immunotherapy Total Addressable Market (TAM)

6. Drugs for Immunotherapy Market Segmentation

6.1. Global Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Interferons
Interleukins
Vaccines
Checkpoint Inhibitors
Other Types
6.2. Global Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer
Autoimmune & Inflammatory Diseases
Infectious Diseases
Other Therapy Areas
6.3. Global Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals & Clinics
Ambulatory Surgical Centers
Other End Users
6.4. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Naked Monoclonal Antibodies
Conjugated Monoclonal Antibodies
Bispecific Monoclonal Antibodies
6.5. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Interferons, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interferon Alfa
Interferon Beta
Interferon Gamma
6.6. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Interleukins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interleukin-2 (IL-2)
Interleukin-6 (IL-6)
Interleukin-12 (IL-12)
6.7. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Preventive Vaccines
Therapeutic Vaccines
6.8. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
6.9. Global Drugs for Immunotherapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Cell Therapies
Cytokine Therapy
T-Cell Receptor Therapy

7. Drugs for Immunotherapy Market Regional And Country Analysis

7.1. Global Drugs for Immunotherapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Drugs for Immunotherapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drugs for Immunotherapy Market

8.1. Asia-Pacific Drugs for Immunotherapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drugs for Immunotherapy Market

9.1. China Drugs for Immunotherapy Market Overview
9.2. China Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drugs for Immunotherapy Market

10.1. India Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drugs for Immunotherapy Market

11.1. Japan Drugs for Immunotherapy Market Overview
11.2. Japan Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drugs for Immunotherapy Market

12.1. Australia Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drugs for Immunotherapy Market

13.1. Indonesia Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drugs for Immunotherapy Market

14.1. South Korea Drugs for Immunotherapy Market Overview
14.2. South Korea Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drugs for Immunotherapy Market

15.1. Western Europe Drugs for Immunotherapy Market Overview
15.2. Western Europe Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drugs for Immunotherapy Market

16.1. UK Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drugs for Immunotherapy Market

17.1. Germany Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drugs for Immunotherapy Market

18.1. France Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drugs for Immunotherapy Market

19.1. Italy Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drugs for Immunotherapy Market

20.1. Spain Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drugs for Immunotherapy Market

21.1. Eastern Europe Drugs for Immunotherapy Market Overview
21.2. Eastern Europe Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drugs for Immunotherapy Market

22.1. Russia Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drugs for Immunotherapy Market

23.1. North America Drugs for Immunotherapy Market Overview
23.2. North America Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drugs for Immunotherapy Market

24.1. USA Drugs for Immunotherapy Market Overview
24.2. USA Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drugs for Immunotherapy Market

25.1. Canada Drugs for Immunotherapy Market Overview
25.2. Canada Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drugs for Immunotherapy Market

26.1. South America Drugs for Immunotherapy Market Overview
26.2. South America Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drugs for Immunotherapy Market

27.1. Brazil Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drugs for Immunotherapy Market

28.1. Middle East Drugs for Immunotherapy Market Overview
28.2. Middle East Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drugs for Immunotherapy Market

29.1. Africa Drugs for Immunotherapy Market Overview
29.2. Africa Drugs for Immunotherapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Drugs for Immunotherapy Market, Segmentation By Therapy Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Drugs for Immunotherapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drugs for Immunotherapy Market Competitive Landscape And Company Profiles

30.1. Drugs for Immunotherapy Market Competitive Landscape
30.2. Drugs for Immunotherapy Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Drugs for Immunotherapy Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc
31.2. Eli Lilly and Company
31.3. Bristol-Myers Squibb
31.4. AstraZeneca plc
31.5. Johnson & Johnson
31.6. UbiVac
31.7. Pfizer Inc.
31.8. Sanofi SA
31.9. Bayer AG
31.10. Celgene Corporation
31.11. Incyte Corporation
31.12. Juno Therapeutics Inc.
31.13. Bluebird bio
31.14. Celldex Therapeutics
31.15. BeiGene

32. Global Drugs for Immunotherapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drugs for Immunotherapy Market

34. Recent Developments In The Drugs for Immunotherapy Market

35. Drugs for Immunotherapy Market High Potential Countries, Segments and Strategies

35.1 Drugs for Immunotherapy Market In 2029 - Countries Offering Most New Opportunities
35.2 Drugs for Immunotherapy Market In 2029 - Segments Offering Most New Opportunities
35.3 Drugs for Immunotherapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer